Qiagen N.V. Stock News

Increased application areas of biobank samples, increased financing from commercial and government organisations for biobanking, increased genomic research efforts, and increased investment in R&D activities by various healthcare firms are all driving the global biobanking market forward. Due to increased adoption

Destiny Wealth Partners LLC purchased a new position in QIAGEN (NYSE:QGEN) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 1,000 shares of the companys stock, valued at approximately $52,000. Other institutional investors have also recently made changes to their []

The investment included participation from existing and new investors, including the Qatar Investment Authority (QIA) - which will support the company''s expansion to countries in the Middle East. The post Infarm raises $200M to accelerate vertical farm expansion appeared first on FreshFruitPortal.com . Keep reading

DUBLIN--(BUSINESS WIRE)--The "Precision Medicine Global Market Report 2021: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com''s offering. The global precision medicine market is expected to grow from $62.75 billion in 2020 to $72.58 billion in 2021 at a compound annual growth rate (CAGR) of 15.7%. The market is expected to reach $118.32 billion in 2025 at a CAGR of 13%. Major players in the precision medicine market are Qiagen, Novartis AG, Medtronic, AstraZeneca plc.,

QIAGEN (NYSE:QGEN) and Repligen (NASDAQ:RGEN) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, institutional ownership, dividends, valuation and risk. Earnings & Valuation This table compares QIAGEN and Repligens revenue, earnings per share and valuation. Gross Revenue []

Key Companies in Next-Generation Sequencing Market are Illumina, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., QIAGEN, BGI, PerkinElmer Inc., Eurofins Scientific, Macrogen, Inc., PierianDx Key Companies in Next-Generation Sequencing Market are Illumina, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., QIAGEN, BGI, PerkinElmer Inc., Eurofins Scientific, Macrogen, Inc., PierianDx

Key Companies in PCR Market are Agilent Technologies, Inc., Qiagen, Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., Sysmex Inostic, Abbott, Thermo Fischer Scientific Inc., Eppendorf AG, Other players Key Companies in PCR Market are Agilent Technologies, Inc., Qiagen, Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., Sysmex Inostic, Abbott, Thermo Fischer Scientific Inc., Eppendorf AG, Other players

DUBLIN--(BUSINESS WIRE)--The "Isothermal Nucleic Acid Amplification Technology (INAAT) Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com''s offering. The global isothermal nucleic acid amplification technology (INAAT) market is expected to grow from $2.36 billion in 2020 to $2.62 billion in 2021 at a compound annual growth rate (CAGR) of 11%. The market is expected to reach $4.03 billion in 2025 at a CAGR of 11.4%. Major players in the

QIAGEN (QGEN) will develop a diagnostic assay that can identify the Denovo Genomic Marker 1 in patients with lymphoid cancer.

QIAGEN (QGEN) will develop a diagnostic assay that can identify the Denovo Genomic Marker 1 in patients with lymphoid cancer.

SAN DIEGO and GERMANTOWN, Md. and HILDEN, Germany, Dec. 9, 2021 /PRNewswire/ -- Denovo Biopharma LLC and QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a collaboration to develop a blood-based companion diagnostic (CDx) test to identify patients expressing Denovo…

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Committee Votes Against Recommending Approval Of Kidney Disease Drug Reata Pharmaceuticals, Inc.

QIAGEN''s blood-based test will help to identify patients with Diffuse Large B-Cell Lymphoma (DLBCL) likely to respond to Denovo''s new investigational cancer treatment DB102TM The partners seek FDA

Related Stocks: MRK , AZN , IDXX , GILD , CRL , PHG , MRNA , GH , QGEN , ALKS , BHVN , STVN , MTD , VRTX , QURE , ALXN , A , STE ,